Key result
Sleeve gastrectomy linked to ~63% excess weight loss and metabolic syndrome resolution at 12 months.
Why the study?
Obesity and its correlation with metabolic syndrome increase the risk of major cardiovascular complications, and the effects of laparoscopic sleeve gastrectomy on metabolic parameters need evaluation.
Does laparoscopic sleeve gastrectomy improve weight and metabolic parameters in patients with morbid obesity and metabolic syndrome?
Cohort (n=23)
Does laparoscopic sleeve gastrectomy improve weight and metabolic parameters in patients with morbid obesity and metabolic syndrome?
Laparoscopic sleeve gastrectomy is associated with significant weight loss and resolution of metabolic syndrome in patients with morbid obesity at 12 months.
Answers are grounded in this paper and cite their sources.
May support LSG consideration in morbid obesity with metabolic syndrome; leaves open durability and generalizability in RCTs.
PURPOSES: Obesity and its correlation with other pathological conditions determine the onset of the metabolic syndrome, which exposes the patient to a higher risk of major cardiovascular complications. Laparoscopic sleeve gastrectomy (LSG) is a bariatric surgical procedure that appears to influence both the reduction of fat mass and the action of some gastrointestinal hormones. PATIENTS AND METHODS: Between January 2011 and July 2013, 23 patients with morbid obesity underwent LSG and follow-up. In the evaluation of patients, the criteria for metabolic syndrome given by the International Diabetes Federation were followed. A multidisciplinary team of experts evaluated patients before surgery and in subsequent scheduled postoperative visits at 7, 30, 60, and 90 days and 4, 5, 6, 9, and 12 months. Anthropometric and metabolic parameters were analyzed. RESULTS: The mean excess weight loss was 8.57±3.02%, 17.65±6.40%, 25.47±7.90%, 33.76±9.27%, 41.83±10.71%, 46.02±13.90%, 52.60±14.05%, 58.48±16.07%, and 62.59±21.29% at 7, 30, 60, and 90 days and 4, 5, 6, 9, and 12 months, respectively. In the same observational period there was an excellent improvement of metabolic indices. None of the patients previously taking prescribed hypoglycemic drugs restarted therapy. Mean fasting plasma glucose significantly decreased compared with the preoperative values. Blood pressure had a statistically significant improvement. Modification in the lipid profile was more variable. During the period of observation 22 of 23 patients reported in this study did not fit the criteria for metabolic syndrome. CONCLUSIONS: Morbid obesity and related diseases may benefit from a surgical approach in selected patients. Randomized controlled trials are needed to evaluate the role of LSG.
No takes yet. Share an insight, caveat, or question.
Desiderio et al. (2013) conducted a cohort in Morbid obesity and metabolic disorders (n=23). Laparoscopic sleeve gastrectomy was evaluated on Excess weight loss at 12 months. Laparoscopic sleeve gastrectomy resulted in a mean excess weight loss of 62.59% at 12 months, with 22 of 23 patients no longer meeting criteria for metabolic syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: